BioCentury This Week

BioCentury Podcasts
  • 4.9 (28)
  • LIFE SCIENCES
  • UPDATED WEEKLY
BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

  1. Ep. 298 - Takeaways from the 25th Bio€quity Europe

    19H AGO

    Ep. 298 - Takeaways from the 25th Bio€quity Europe

    Political and market turmoil has raised questions whether the U.S. can retain its biopharma leadership position, and in turn presents Europe with an opportunity to attract talent back to the continent with an offer of a more stable biomedical funding and regulatory environment. Jeito Capital’s Ksenija Pavletic and Cambridge Innovation Capital’s Anne Horgan join BioCentury’s analyst to wrap up the 25th annual Bio€quity Europe conference in Bruges, Belgium, by discussing their key takeaways from the two-day event. This episode was sponsored by Jeito Capital. View full story: https://www.biocentury.com/article/655998 #biotech #biopharma #pharma #lifescience #networking 00:01 - Sponsor Message: Jeito Capital 02:10 - Key Takeaways 09:13 - Challenges and Opportunities for Europe 19:23 - Capital Efficiency and Success Stories 28:27 - Leadership, Teams & Talent To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    39 min
  2. Ep. 297 - European Biotech's Moment? Plus: Biomarin, Boston Deals & Novo Nordisk CEO

    3D AGO

    Ep. 297 - European Biotech's Moment? Plus: Biomarin, Boston Deals & Novo Nordisk CEO

    The turbulence that has come with the Trump administration’s policies related to the U.S. biopharmaceutical industry is creating an opening for Europe to bolster its life sciences industry. On the latest BioCentury This Week podcast, BioCentury’s editors look at how Europe can capitalize on staffing cuts at FDA and NIH and an uncertain policy environment to lure back talent to bolster regulatory agencies and biotech R&D engines and attract assets and partners from China. The editors also discuss two biotech deals driven by former leaders of BD at Roche, Biomarin's James Sabry and Sophie Kornowski at Boston Pharmaceuticals. Under the leadership of Sabry and CEO Alexander Hardy, Biomarin delivered its first takeout in a decade by acquiring Inozyme as it positions itself to take advantage of a regulatory and policy environment that they believe is favorable to their rare disease strategy. CEO Kornowski, meanwhile, executed on a plan to focus her company on a single liver disease asset that GSK acquired for $1.2 billion up front. Finally, BioCentury’s editors discuss the management shake-up at obesity company Novo Nordisk, where Lars Fruergaard Jørgensen, the leader who spearheaded Novo Nordisk’s transformation into a dominant player in obesity, is stepping down. Chan Zuckerberg Chicago Biohub is hosting an exclusive, invite-only reception on June 3 — the eve of BioCentury's Grand Rounds conference — gathering top voices in biotech innovation and investment to exchange bold ideas, spark new collaborations and channel the energy of Chicago’s thriving innovation ecosystem. If you’re interested in attending, please register here. This episode was sponsored by Jeito Capital. View full story: https://www.biocentury.com/article/655964 #biotech #biopharma #pharma #lifescience #politics #policy #law 00:01 - Sponsor Message: Jeito Capital 05:05 - European Biotech's Moment? 19:00 - Boston Pharma, Biomarin Deals 29:41 - Novo Nordisk CEO To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    36 min
  3. Ep. 296 - Trends in Obesity, Vinay Prasad at FDA, Ovarian Cancer Insights

    MAY 13

    Ep. 296 - Trends in Obesity, Vinay Prasad at FDA, Ovarian Cancer Insights

    Biopharmas developing therapies for obesity are looking to a future where the quality of weight loss matters as much as the quantity — what targets and programs could help realize that vision? On the latest BioCentury This Week podcast, BioCentury’s editors discuss the signaling pathways that may exclusively target fat mass while preserving, or even increasing, lean mass — and which companies are playing in the space. The editors also assess what Vinay Prasad’s past comments say about how he might lead FDA’s Center for Biologics Evaluation and Research (CBER) — and examine how investors are evaluating the possibility that he might move the bar for regulatory approvals. The team then introduces the first in a new BioCentury series, with a look at a Literature Dive into ovarian cancer “atlases” — large-scale molecular profiling studies that point to predictive signatures and patient stratification strategies. This episode was sponsored by Jeito Capital. View full story: https://www.biocentury.com/article/655898 #biotech #biopharma #pharma #obesity #FDA #CBER #LifeScience #OvarianCancer 00:01 - Sponsor Message: Jeito Capital 03:22 - Obesity: Quality over Quantity 15:47 - Prasad at FDA 27:58 - Ovarian Cancer Atlases To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    33 min
  4. Ep. 295 - Bio€quity Europe 2025 Preview

    MAY 9

    Ep. 295 - Bio€quity Europe 2025 Preview

    This year’s Bio€quity Europe conference — the 25th edition of the event — will focus on what’s next for Europe amid biotech’s current complex moment, Editor in Chief Simone Fishburn said on a special edition of the BioCentury This Week podcast previewing the meeting, which kicks off May 12 in Bruges, Belgium. McKinsey & Co.’s Alexandra Zemp and Henk Joos, an investment specialist at Medvia, which fosters health innovation in Flanders, joined BioCentury to discuss the state of Belgium’s biopharma ecosystem and preview some of the conference’s networking events, fireside chats and panel discussions. Claire Macht, portfolio director, Europe, of BioCentury’s conference partner EBD Group, also joined the podcast to detail what to expect in terms of one-on-one partnering meetings at the event. Bio€quity Europe 2025 is sold out, but space on the waitlist remains, and digital passes are available. See the conference website for more information. View full story: https://www.biocentury.com/article/655883 #biotech #biopharma #pharma #networking #LifeScience 00:00 - Introduction 01:25 - What's Next for Europe? 06:58 - Belgium's Biotech Ecosystem 10:29 - McKinsey on European Biotech 15:27 - Partnering, Panels of Note To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    29 min
  5. Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing

    MAY 6

    Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing

    Among the formerly undruggable targets gaining translational momentum, SMARCA2 has intrigued researchers for its potential to treat challenging solid tumors. On the latest BioCentury This Week podcast, BioCentury's editors zero in on preclinical research supporting different degraders of SMARCA2 at this year’s American Association for Cancer Research (AACR) annual meeting. They also discuss takeaways from Editor in Chief Simone Fishburn’s conversation with David Baker, the Nobel-prizewinning pioneer in protein design, and Steve Usdin reports that pharmaceutical industry executives are in a state of alarm over President Trump’s push to include a “most favored nation” policy for Medicaid drug purchases in budget reconciliation legislation. Usdin also discusses why industry executives are confident of a fix for the Inflation Reduction Act’s “pill penalty” and FDA Commissioner Marty Makary’s decision to reject proposals to reorganize the agency. This episode was sponsored by Jeito Capital. View full story: https://www.biocentury.com/article/655851 #biotech #biopharma #pharma #LifeScience #RandD #DrugDevelopment #AACR #SMARCA2 00:01 - Sponsor Message: Jeito Capital 03:01 - AACR Spotlight 11:21 - David Baker Protein Design 19:12 - Trump's Drug Pricing Plan To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    31 min
  6. Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs

    APR 29

    Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs

    Belief in tau — both as a target and surrogate endpoint — for Alzheimer’s is building among leaders in the field. On the latest BioCentury This Week podcast, Executive Editor Selina Koch discusses how tau could be reaching a tipping point. Also on this week’s episode, Washington Editor Steve Usdin details how political moves have begun to intrude into the Trump administration’s regulation of vaccines, a topic that’s also taken up by Phil Krause and Luciana Borio in a BioCentury Guest Commentary published Monday. BioCentury’s editors then discuss delays for drug regulation at FDA, Merck KGaA's $3.9 billion deal to acquire Springworks, and why biotech IPOs could soon have a moment in Hong Kong. This episode of BioCentury This Week podcast is sponsored by RemeGen. View full story: https://www.biocentury.com/article/655780 #biotech #biopharma #pharma #lifescience #alzheimers #RandD #DrugDevelopment #IPO 00:01 - Sponsor Message: RemeGen Co. 02:06 - Tau Time for Alzheimer's 13:10 - Vaccine Drama at FDA 23:32 - Merck KGaA's SpringWorks Buy 24:52 - Hong Kong Biotech IPOs To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    31 min
  7. Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview

    APR 26

    Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview

    Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare autoimmune neuromuscular disease coming at this month’s American Academy of Neurology. On a special episode of the BioCentury This Week podcast, BioCentury’s editors discuss the landscape for MG therapies, including anti-BLyS and APRIL therapy telitacicept from Remegen. Joining BioCentury’s editors are Qing Zuraw, chief development officer of podcast sponsor RemeGen, and Amit Sachdev, PI on global trials of the biotech’s therapy. BioCentury’s editors also preview the American Association for Cancer Research annual meeting, where degraders and bispecifics are defining translational trends at this year’s event. This episode of BioCentury This Week podcast was sponsored by RemeGen. View full story: https://www.biocentury.com/article/655751 #biotech #biopharma #pharma #lifescience #AAN #AACR 00:01 - Sponsor Message: RemeGen Co. 01:02 - Myasthenia Gravis at AAN 08:31 - RemeGen's Telitacicept 18:03 - AACR: Targets and Trends To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    26 min
  8. Ep. 291 - Grand Rounds - U.S. Preview

    APR 25

    Ep. 291 - Grand Rounds - U.S. Preview

    The academia-industry interface is more important than ever for sustaining biomedical innovation’s forward momentum, even as the Trump administration injects turbulence into academic funding for universities. On a special edition of the BioCentury This Week podcast, BioCentury’s Simone Fishburn and Karen Tkach Tuzman preview Grand Rounds, BioCentury’s second annual R&D conference, along with special guests. Spots are filling up for the Grand Rounds U.S. Presenting Company Class of 2025. Find out how to apply here. View full story: https://www.biocentury.com/article/655696 #biotech #biopharma #pharma #lifescience #academia #chicago #asco 00:00 - Introduction 01:42 - Key Themes and Featured Sessions 07:37 - Chicago's Role in Biotech Innovation 15:06 - McKinsey's Insights 25:18 - Upcoming Events and Networking Opportunities To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    31 min
See All (308)

4.9
out of 5
28 Ratings

About

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Information

More From BioCentury Podcasts

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada